07:55 AM EDT, 04/03/2025 (MT Newswires) -- MoonLake Immunotherapeutics ( MLTX ) said Thursday it entered into an agreement for a facility of up to $500 million from Hercules Capital ( HTGC ) .

MoonLake said that $75 million was drawn down at the transaction's close and that additional tranches will become available upon the company achieving certain milestones.

The company said the additional capital will support the expected launch of sonelokimab in 2027, additional clinical trials, and further investments for growth.